Taligen Therapeutics Inc., an Aurora, Colo.-based drug company focused on modulation and control of the compliment system, has raised $65 million in Series B funding. Alta Partners and Clarus Ventures co-led the deal, and were joined by return backers Sanderling Ventures, Tango and High Country Ventures.
The round is tranched-out, with only about $6 million actually called down so far.
Taligen originally was only seeking $25 million, but CEO Woody Emlen says that company wanted to expand Taligen's potential product suite, which means that it cane “give close to near-equal attention” to a variety of several molecules. “We had felt constrained by the $25 million, and now have much more flexibility.”